-
Oct 21, 2024 | 
ard.bmj.com | Antonis Fanouriakis |George Bertsias |Dimitrios T. Boumpas
Response to: Correspondence on ‘EULAR recommendations for the management of systemic lupus erythematosus: 2023 update’ by Fanouriakis et al Free Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
-
Sep 30, 2024 | 
ard.bmj.com | Antonis Fanouriakis |Myrto Kostopoulou |George Bertsias |Dimitrios T. Boumpas
Response to: Correspondence on ‘EULAR recommendations for the management of systemic lupus erythematosus: 2023 update’ by Fanouriakis et al Free Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
-
Sep 19, 2024 | 
ard.bmj.com | Antonis Fanouriakis |George Bertsias |Dimitrios T. Boumpas
Lupus Erythematosus, Systemic Therapeutics Lupus Nephritis We thank Drs Roberts et al for their interest in the updated EULAR recommendations for the management of systemic lupus erythematosus (SLE), and for the important points they raise.1 Prompted by a phrase in the manuscript text, that race, as an ‘immutable’ characteristic, should be taken into account during the choice of therapy for an individual patient with SLE, they argue that racial differences in treatment responses or other...
-
May 22, 2024 | 
ard.bmj.com | Myrto Kostopoulou |Chetan Mukhtyar |George Bertsias |Dimitrios T. Boumpas
DiscussionFor the recent update of the EULAR recommendations for the management of SLE, we performed five different SLRs based on respective PICOs, to cover the most important aspects in the treatment of this challenging disease. HCQ is the backbone treatment for all patients with SLE, while GC are still used in the majority of patients. The current SLR confirmed the beneficial effects of HCQ in lupus, ranging from prevention of infections or thrombosis to improved survival.
-
Apr 5, 2024 | 
ard.bmj.com | Antonis Fanouriakis |Myrto Kostopoulou |George Bertsias |Dimitrios T. Boumpas
Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
-
Aug 14, 2023 | 
specialty.mims.com | Dimitrios T. Boumpas
The new European Alliance of Associations for Rheumatology (EULAR) recommendations for systemic lupus erythematosus (SLE) and lupus nephritis (LN) have adopted a more proactive treatment approach that focuses on early use of biologics to enable faster steroid tapering and preservation of renal function, as well as to minimize the risk of flares and organ damage progression.
-
Jul 13, 2023 | 
ard.bmj.com | Antonis Fanouriakis |Nikolaos Tziolos |George Bertsias |Dimitrios T. Boumpas
http://orcid.org/0000-0003-2696-031XAntonis Fanouriakis1, Nikolaos Tziolos2, George Bertsias3,4, http://orcid.org/0000-0002-9812-4671Dimitrios T Boumpas2 1 Department of Rheumatology, Asklepieion General Hospital, Athens, Greece 2 4th Department of Internal Medicine, "Attikon" University Hospital, Athens, Greece 3 Rheumatology, Clinical Immunology and Allergy, University of Crete School of Medicine, Iraklio, Greece 4 Laboratory of Autoimmunity-Inflammation, Institute of Molecular Biology and...
-
May 11, 2023 | 
ard.bmj.com | Myrto Kostopoulou |Antonis Fanouriakis |George Bertsias |Dimitrios T. Boumpas
http://orcid.org/0000-0002-8832-7475Myrto Kostopoulou1, http://orcid.org/0000-0003-2696-031XAntonis Fanouriakis1,2, George Bertsias3,4, http://orcid.org/0000-0002-9812-4671Dimitrios T Boumpas1,5 1 Rheumatology and Clinical Immunology, National and Kapodistrian University, Athens, Greece 2 First Department of Propaedeutic Internal Medicine, National and Kapodistrian University, Athens, Greece 3 Rheumatology, University of Crete School of Medicine, Iraklio, Greece 4 Laboratory of...
-
Apr 24, 2023 | 
ard.bmj.com | Myrto Kostopoulou |Antonis Fanouriakis |George Bertsias |Dimitrios T. Boumpas
Part I: pathogenesis and novel molecular targets: new and old playersWhy do some patients with SLE develop LN? The interaction of genes and environmentLN has a high genetic loadPatients with SLE with severe disease—including nephritis—have a high genetic risk score—calculated based on 57 SLE risk loci—and are more likely to develop lupus earlier, accrue damage and have decreased survival.
-
Apr 24, 2023 | 
ard.bmj.com | Myrto Kostopoulou |Antonis Fanouriakis |George Bertsias |Dimitrios T. Boumpas
Part I: pathogenesis and novel molecular targets: new and old playersWhy do some patients with SLE develop LN? The interaction of genes and environmentLN has a high genetic loadPatients with SLE with severe disease—including nephritis—have a high genetic risk score—calculated based on 57 SLE risk loci—and are more likely to develop lupus earlier, accrue damage and have decreased survival.
